Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer
Explore this paper's citation graph
Summary
These results suggest a rationale for future studies on the potential therapeutic applications of PDE inhibitors in men with prostate cancer, and determine their potential role in hypoxia-mediated chemoresistance and immune escape.
- Type
- article
- Published
- 2013-04-01
- Cited by
- 44
- References
- 35
- OpenAlex
- https://openalex.org/W22383129
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24752402
Keywords
Aesthetics, Visual arts, Computer science, Art
References
- Mechanisms of multidrug resistance in cancer.
- A simple direct assay of 3',5'-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography.
- Multi-Drug Resistance in Cancer
- Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and suceptibility to a mitochondrial toxin
- Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
- Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination
- Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.
- Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide.
- Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer.
- Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age
- Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells.
- Abstract 447: A mechanism of hypoxia-induced immune escape in cancer cells
- Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.
- Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
- Soluble MICA in malignant diseases
- Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model.
- Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate.
- Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
- HIF-1 and tumor progression: pathophysiology and therapeutics.
Cited by
- Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
- PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
- Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models.
- Clinical and molecular genetics of the phosphodiesterases (PDEs).
- Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model
- Phosphodiesterase sequence variants may predispose to prostate cancer
- Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence
- Transcriptional response networks for elucidating mechanisms of action of multitargeted agents.
- Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?
- Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition.
- Novel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study.
- Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis
- Microarray analysis of copy-number variations and gene expression profiles in prostate cancer
- Phosphodiesterase type 5 and cancers: progress and challenges
- Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
- Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia
- Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
- Phosphodiesterases and cAMP Pathway in Pituitary Diseases
- Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
- The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It?